Stomach Cancer Medications
Here's a list of the approved drugs to treat stomach cancer. Click on any of the medications for more info on indications, dosing and side effects.
Quick Filter
*generic version available
E experimental
Chemotherapy Medications
Immunotherapy Medications
Targeted Therapy Medications
Chemotherapy Medications More >>
DRUG Chemotherapy |
---|
GENERIC NAME Multiple |
DRUG INDICATION
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here. |
Immunotherapy Medications More >>
DRUG Keytruda |
---|
GENERIC NAME pembrolizumab |
DRUG INDICATION
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. |
DRUG Opdivo |
---|
GENERIC NAME nivolumab |
DRUG INDICATION
Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. |
Targeted Therapy Medications More >>
DRUG Cyramza |
---|
GENERIC NAME ramucirumab |
DRUG INDICATION
Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer. |
DRUG Enhertu |
---|
GENERIC NAME fam-trastuzumab deruxtecan-nxki |
DRUG INDICATION
Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer. |
DRUG Herceptin |
---|
GENERIC NAME trastuzumab |
DRUG INDICATION
Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2. |
DRUG Rozlytrek |
---|
GENERIC NAME entrectinib |
DRUG INDICATION
Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer. |
DRUG Vitrakvi |
---|
GENERIC NAME larotrectinib |
DRUG INDICATION
Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions. |